Avicanna Ignites European Market with Landmark Swiss CBD Flower Export!

In a groundbreaking move that signals a new era for global cannabis trade, Avicanna Inc. ("Avicanna" or the "Company"), a leading biopharmaceutical company focused on plant-derived cannabinoid medicines, announced today that its Colombian subsidiary, Santa Marta Golden Hemp S.A.S. ("SMGH"), has successfully completed the first-ever export of its premium CBD-dominant cannabis flower into Switzerland.

This pivotal export marks a monumental step for Avicanna, solidifying its position in the rapidly expanding European market and significantly enhancing its global supply chain capabilities.

The meticulously cultivated, high-quality CBD flower, renowned for its therapeutic potential, will now be accessible to consumers in Switzerland, a key gateway to the broader European continent.

The successful shipment was facilitated through a strategic and exclusive sales and distribution agreement with EuroMedLabs AG, a distinguished Swiss entity.

This partnership underscores Avicanna's commitment to forging strong international alliances that ensure efficient and compliant market access for its innovative cannabis products. EuroMedLabs AG's expertise in the European pharmaceutical and nutraceutical sectors will be instrumental in distributing Avicanna's premium offerings across Switzerland.

Aras Azadian, CEO of Avicanna, emphasized the profound significance of this achievement.

"This first export of our CBD-dominant cannabis flower into Switzerland is more than just a logistical milestone; it's a testament to our unwavering dedication to quality, compliance, and global expansion," said Azadian. "It represents a critical step in building a robust and diversified global supply chain for high-quality, sustainably sourced medical and wellness cannabis products, and we are thrilled to partner with EuroMedLabs AG to bring our superior flower to the discerning Swiss market."

Avicanna's cultivation operations in Colombia are globally recognized for their commitment to sustainable and Good Agricultural and Collection Practices (GACP).

This rigorous approach ensures that every gram of cannabis flower meets the highest international standards for purity, potency, and safety, a crucial factor for success in highly regulated markets like Switzerland.

Beyond cannabis flower, Avicanna continues to advance its diverse portfolio, which includes the supply of Active Pharmaceutical Ingredient (API) grade CBD and CBG, as well as a range of finished medical cannabis products.

The company's pharmaceutical division remains dedicated to the research, development, and commercialization of advanced cannabinoid-based medicines, further solidifying its reputation as a leader in the biopharmaceutical cannabis space.

This landmark export is not merely a transaction; it's a clear signal of Avicanna's ambitious vision for the future.

By successfully entering the Swiss market, Avicanna is poised for substantial growth and is well on its way to becoming a dominant player in the global medical and wellness cannabis industry, providing patients and consumers worldwide with access to high-quality, science-backed cannabinoid solutions.